The invention relates to the use of an effective amount of mesoprogestins of the types J867, J912, J956 and J1042 for preparing a composition for the treatment of benign hormone-dependent gynecological disorders, such as endometriosis, uter…
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological …
This invention relates to the pharmaceutical use of the fibulin-1 polypeptide and the fibulin-1 nucleic acid in female birth control and for the treatment and diagnosis of endometriosis.
PCT No. PCT/EP95/02998 Sec. 371 Date Jun. 10, 1997 Sec. 102(e) Date Jun. 10, 1997 PCT Filed Jul. 27, 1995 PCT Pub. No. WO96/03130 PCT Pub. Date Feb. 8, 1996This invention relates to the use of a product that contains in combination individu…
The present invention concerns the use of a product containing in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen to be sequentially orally administrated (the competitiv…
The present invention concerns the use of a product containing in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen to be sequentially orally administrated (the competitiv…